Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...

Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

Donald Trump’s electoral victory has shaken the market, mostly in a good way. The S&P 500 gained 5% in the first two days ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Unverified data about events after vaccinations is not evidence that the vaccine caused the event, as suggested in social ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), ...

The Centers for Disease Control and Prevention's (CDC's) 2024-2025 COVID-19 vaccine immunization schedule advises, in the ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

India should focus on enhancing local vaccine manufacturing and research for better control over safety, according to GTRI. They also suggest investigating adverse health events post-vaccination to ...